BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30523399)

  • 1. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
    Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
    World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.
    Tian D; Wang XY; Zong HT; Zhang Y
    Clin Interv Aging; 2017; 12():405-412. PubMed ID: 28260869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
    Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
    Madeira CR; Tonin FS; Fachi MM; Borba HH; Ferreira VL; Leonart LP; Bonetti AF; Moritz RP; Trindade ACLB; Gonçalves AG; Fernandez-Llimos F; Pontarolo R
    World J Urol; 2021 Mar; 39(3):953-962. PubMed ID: 32388784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
    Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
    J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men With Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases.
    Brock G; Ni X; Oelke M; Mulhall J; Rosenberg M; Seftel A; D'Souza D; Barry J
    J Sex Med; 2016 May; 13(5):860-75. PubMed ID: 27114197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
    Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
    Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil Once a Day for Men with Erectile Dysfunction: Is It Superior than On-Demand Administration?
    Prasetyo DT; Raharja PAR; Mantiri BJ; Ringoringo DRL; Rahman IA; Felizio J; Tambunan MP; Fadhly SF; Rahardjo HE
    Acta Med Indones; 2019 Jul; 51(3):275-281. PubMed ID: 31699953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
    Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
    J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
    Kamenov ZA
    J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study.
    Buvat J; Hatzichristou D; Boess FG; Büttner H; Gehchan N; Henneges C; Porst H
    Int J Clin Pract; 2014 Sep; 68(9):1087-99. PubMed ID: 25123817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
    Lombardo R; Tema G; De Nunzio C
    Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial.
    Park HJ; Choi HK; Ahn TY; Park JK; Chung WS; Lee SW; Kim SW; Hyun JS; Park NC
    J Sex Med; 2010 Aug; 7(8):2842-50. PubMed ID: 20626604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis.
    Qiangzhao L; Xiaofeng Z; Fenghai Z; Qiong L; Fa Z; Bohong G; Xinsheng X
    Medicine (Baltimore); 2020 Oct; 99(43):e22834. PubMed ID: 33120811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials.
    Du W; Li J; Fan N; Shang P; Wang Z; Ding H
    Aging Male; 2014 Jun; 17(2):107-11. PubMed ID: 24219508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.